111 related articles for article (PubMed ID: 31925916)
41. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393
[TBL] [Abstract][Full Text] [Related]
42. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
[TBL] [Abstract][Full Text] [Related]
43. Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Stock W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):487-8. PubMed ID: 18654114
[No Abstract] [Full Text] [Related]
44. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
45. Drug Combo May Obviate Chemotherapy in ALL.
Cancer Discov; 2020 Dec; 10(12):OF1. PubMed ID: 33168588
[TBL] [Abstract][Full Text] [Related]
46. Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy.
Wu KH; Wu HP; Weng T; Peng CT; Chao YH
Curr Oncol; 2015 Aug; 22(4):303-6. PubMed ID: 26300669
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
Guo Y; Liu TF; Yang WY; Wang SC; Ruan M; Chen XJ; Zhang L; Liu F; Zou Y; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):634-7. PubMed ID: 26108329
[No Abstract] [Full Text] [Related]
48. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Milone JH; Enrico A
Leuk Lymphoma; 2009 Dec; 50 Suppl 2():9-15. PubMed ID: 20017606
[TBL] [Abstract][Full Text] [Related]
50. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
51. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
52. [An extremely high serum methotrexate concentration associated with acute renal failure in a patient with acute lymphoblastic leukemia after conduction of high dose consolidation].
Pimenova MA; Sokolov AN; Biriukova LS; Ustinova EN; Shaforostova II; Donskova IA; Bogdanov RF; Parovichnikova EN; Savchenko VG
Ter Arkh; 2011; 83(7):58-61. PubMed ID: 21894753
[TBL] [Abstract][Full Text] [Related]
53. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
54. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia.
Forghieri F; Luppi M; Potenza L
Hematology; 2015 Dec; 20(10):618-9. PubMed ID: 26574786
[No Abstract] [Full Text] [Related]
55. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
56. Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Wang T; Cheng C; Peng L; Gao M; Xi M; Rousseaux S; Khochbin S; Wang J; Mi J
J Cell Mol Med; 2018 Mar; 22(3):1614-1626. PubMed ID: 29266867
[TBL] [Abstract][Full Text] [Related]
57. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
58. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
59. Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimokaze T; Mitsui T; Takeda H; Kawakami T; Arai T; Ito M; Iwaba A; Izumino H; Takahashi N; Kanno M; Sendo D; Hayasaka K
Pediatr Hematol Oncol; 2009 Sep; 26(6):448-53. PubMed ID: 19657995
[No Abstract] [Full Text] [Related]
60. Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Li H; Zhang W; Yi D; Ye Y; Xiao X
Leuk Lymphoma; 2017 Apr; 58(4):1005-1007. PubMed ID: 27658493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
